NeuroPace RNS System Revenue Rises 1.4% in Q3 to $22.9 Million
Key Facts
NeuroPace reported RNS system revenue of $22.9 million in the third quarter of 2026, up 1.4% from the same period a year earlier, according to the company’s earnings release dated November 12. The company lowered its full-year revenue guidance, signaling that slower sales during the quarter affected its outlook for the remainder of the year. Chief Executive Joel Becker said the shortfall was concentrated in several of the company’s largest accounts. He added that changes to the sales team’s organization caused more disruption than management had expected. Scheduled cases for the fourth quarter have begun to recover, he said.
The company’s business centers on the RNS System, a platform that responds to brain activity and delivers personalized, real-time treatment at the source of a seizure, targeting patients with drug-resistant epilepsy. That business makes performance at large accounts and sales team organization direct factors in the pace of quarterly revenue. In the third quarter, system revenue grew 1.4% year over year. In the second quarter, management said growth in the core RNS business was tied to increased adoption in the existing focal epilepsy indication. At the time, it reported new records for active prescribers, accounts and patient pipeline.
On profitability, NeuroPace posted a GAAP net loss of $3.3 million in the third quarter, compared with a loss of $4.9 million in the same period of 2025. Adjusted EBITDA also turned positive at $0.4 million, after a loss of $1.3 million a year earlier. Both comparisons reflect an improvement in net loss and on the adjusted earnings measure during the period. This came alongside slower growth in the company’s core system revenue. Scheduled cases for the fourth quarter have begun to recover after disruption accompanying changes to the sales team’s organization, Becker said.
On product and regulatory updates, the company said it submitted a premarket approval supplement for its Remote Care service to the U.S. Food and Drug Administration. The company is using a planned 180-day review cycle for the application. It also plans to submit an amendment to its expansion filing to include patients with idiopathic generalized epilepsy near year-end, following the October SIR meeting. In the market, NeuroPace shares closed at $12.52 on November 11, the session before the earnings announcement. The regulatory update and planned filing were among the developments the company announced alongside its third-quarter results and revised annual guidance.